Table 3.

Over-68 hypertensive Covid-19 patients cross-stratified by outcome status (rows) and according to as they do not use RASIs (column 2), or use ACEIs but not ARBs (column 3), or use ACEIs but not ARBs (column 4). Reported in brackets are stratum-specific crude mortality estimates.

Outcome	RASI non-users	ACEIs	ARBs
	(mortality)	(mortality)	(mortality)
Survived	69	83	74
Decedent	90	61	46
	(56%)	(42%)	(38%)

RASI: renin aldosterone system inhibitor; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.